Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 26;21(1):463.
doi: 10.1186/s12885-021-08162-3.

Trastuzumab administration during pregnancy: an update

Angeliki Andrikopoulou  1   2 , Kleoniki Apostolidou  1   2 , Spyridoula Chatzinikolaou  2 , Garyfalia Bletsa  3 , Eleni Zografos  1   2 , Meletios-Athanasios Dimopoulos  1   2 , Flora Zagouri  4   5
Affiliations

Trastuzumab administration during pregnancy: an update

Angeliki Andrikopoulou et al. BMC Cancer. .

Erratum in

Abstract

Background: Over than one third (28-58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However, FDA has categorized Trastuzumab as a category D drug for pregnant patients with breast cancer. This systemic review aims to synthesize all currently available data of trastuzumab administration during pregnancy and provide an updated view of the effect of trastuzumab on fetal and maternal outcome.

Methods: Eligible articles were identified by a search of MEDLINE bibliographic database and ClinicalTrials.gov for the period up to 01/09/2020; The algorithm consisted of a predefined combination of the words "breast", "cancer", "trastuzumab" and "pregnancy". This study was performed in accordance with the PRISMA guidelines.

Results: A total of 28 eligible studies were identified (30 patients, 32 fetuses). In more than half of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration during gestation was 15.7 weeks (SD: 10.8; median: 17.5; range: 1-32). Oligohydramnios or anhydramnios was the most common (58.1%) adverse event reported in all cases. There was a statistically significant decrease in oligohydramnios/anhydramnios incidence in patients receiving trastuzumab only during the first trimester (P = 0.026, Fisher's exact test). In 43.3% of cases a completely healthy neonate was born. 41.7% of fetuses exposed to trastuzumab during the second and/or third trimester were born completely healthy versus 75.0% of fetuses exposed exclusively in the first trimester. All mothers were alive at a median follow-up of 47.0 months (ranging between 9 and 100 months). Of note, there were three cases (10%) of cardiotoxicity and decreased ejection fraction during pregnancy.

Conclusions: Overall, treatment with trastuzumab should be postponed until after delivery, otherwise pregnancy should be closely monitored.

Keywords: Breast cancer; Gestation; Oligohydramnios; Pregnancy; Trastuzumab; her2.

PubMed Disclaimer

Conflict of interest statement

MAD has received honoraria from participation in advisory boards from Amgen, Bristol-Myers-Squibb, Celgene, Janssen, Takeda. FZ has received honoraria for lectures and has served in an advisory role for Astra-Zeneca, Eli-Lilly, Merck, Novartis, Pfizer, and Roche. The remaining authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart presenting the successive steps during the selection of studies
See this image and copyright information in PMC

References

    1. Navrozoglou I, Vrekoussis T, Kontostolis E, Dousias V, Zervoudis S, Stathopoulos EN, Zoras O, Paraskevaidis E. Breast cancer during pregnancy: a mini-review. Eur J Surg Oncol. 2008;34(8):837–843. doi: 10.1016/j.ejso.2008.01.029. - DOI - PubMed
    1. Ring AE, Smith IE, Ellis PA. Breast cancer and pregnancy. Ann Oncol. 2005;16(12):1855–1860. doi: 10.1093/annonc/mdi388. - DOI - PubMed
    1. Elledge RM, Ciocca DR, Langone G, McGuire WL. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer. 1993;71(8):2499–2506. doi: 10.1002/1097-0142(19930415)71:8<2499::AID-CNCR2820710812>3.0.CO;2-S. - DOI - PubMed
    1. Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98(5):1055–1060. doi: 10.1002/cncr.11614. - DOI - PubMed
    1. Shousha S. Breast carcinoma presenting during or shortly after pregnancy and lactation. Arch Pathol Lab Med. 2000;124. 10.1043/0003-9985(2000)124<1053:BCPDOS>2.0.CO;2. - PubMed

Publication types

MeSH terms